Cardiac Monitors in North Carolina

Myocardial Solutions develops MyoStrain®, a proprietary cardiac software platform that leverages MRI imaging data to quantify myocardial strain and assess cardiac function. The platform is designed to enable early detection and proactive management of cardiac dysfunction in at-risk and asymptomatic patient populations. MyoStrain performs rapid (approximately 10-minute), quantitative assessment of myocardial function using segmental intra-myocardial strain analysis. The software supports clinical decision-making in cardiology and cardio-oncology applications, helping physicians identify subtle changes in cardiac performance before symptoms manifest, thereby enabling earlier intervention and improved patient outcomes. The company targets standardization of preventative cardiac care delivery within healthcare systems, supporting enhanced clinical efficiency, cost reduction, and improved reimbursement models. Products are supported by clinical presentations, peer-reviewed publications, and conference presentations demonstrating clinical validation and utility.

Aleva Neurotherapeutics SA is a Swiss medical device company specializing in Directional Deep Brain Stimulation (DBS) systems for treatment of neurological and psychiatric disorders. The company was founded as a spin-off from the Swiss Federal Institute of Technology in Lausanne and manufactures the directSTIM™ DBS system, featuring a proprietary 24-contact directional lead with Multiple Independent Current Control (MICC) generator technology. The system enables physicians to deliver highly precise directional stimulation, improving therapeutic benefits while minimizing side effects and reducing non-responder patient rates and revision procedures. Aleva holds 13 patent families and 90 granted patents in DBS technology. The directSTIM™ system has obtained CE marking for European distribution and MRI approval. Manufacturing and headquarters are located in Lausanne, Switzerland, leveraging the country's precision manufacturing expertise. The company targets neurologists and neurosurgeons in Europe and aims to expand to additional worldwide markets. Aleva positions itself as a specialized, responsive partner focused on addressing the clinical challenges faced by healthcare professionals treating Parkinson's disease and other neurological conditions requiring neuromodulation therapy.